Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer

NCT ID: NCT00030485

Last Updated: 2014-01-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2002-01-31
• Study Completion Date: 2007-04-30

Brief Summary

RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.

PURPOSE: Phase II trial to determine the effectiveness of erlotinib in treating patients who have locally advanced and/or metastatic endometrial cancer.

Detailed Description

OBJECTIVES:

• Determine the efficacy of erlotinib, in terms of response rate and duration of stable disease, in patients with locally advanced and/or metastatic carcinoma of the endometrium.
• Determine the toxicity of this drug in these patients.
• Determine the time to progression and duration of response in patients treated with this drug.
• Correlate objective tumor response with levels of epidermal growth factor receptor expression in patients treated with this drug.

OUTLINE: This is a multicenter study.

Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients are followed at 4 weeks. Patients with complete or partial response or stable disease are also followed every 3 months until relapse or death.

PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 12-18 months.

Conditions

Endometrial Cancer

Study Design

• Primary Study Purpose: TREATMENT

Interventions

erlotinib hydrochloride

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed metastatic and/or locally advanced adenocarcinoma or adenosquamous carcinoma of the endometrium

• Incurable by standard therapies
• Clinically and/or radiologically documented disease with at least 1 unidimensionally measurable site

• At least 20 mm by x-ray, physical exam, or CT scan OR
• At least 10 mm by spiral CT scan
• Bone metastases considered nonmeasurable
• Tumor tissue from primary tumor available for assessing epidermal growth factor receptor (EGFR) status
• No uterine sarcomas (leiomyosarcoma), mixed mullerian tumors, and/or adenosarcomas
• No known brain metastases

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• ECOG 0-2

Life expectancy:

• At least 12 weeks

Hematopoietic:

• Platelet count at least 100,000/mm3
• Absolute granulocyte count at least 1,500/mm3

Hepatic:

• Bilirubin no greater than upper limit of normal (ULN)
• AST/ALT no greater than 2.5 times ULN

Renal:

• Creatinine no greater than 1.5 times ULN

Cardiovascular:

• No symptomatic congestive heart failure
• No unstable angina
• No cardiac arrhythmia

Gastrointestinal:

• No gastrointestinal (GI) tract disease that would preclude ability to take oral medication
• No requirement for IV alimentation
• No uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)
• No active peptic ulcer disease

Ophthalmic:

• No significant ophthalmologic abnormalities, including any of the following:

• Prior severe dry eye syndrome, Sjogren's syndrome, or keratoconjunctivitis sicca
• Severe-exposure keratopathy
• Disorders that would increase the risk of epithelium-related complications (e.g., bullous keratopathy, aniridia, severe chemical burns, or neutrophilic keratitis)
• Congenital abnormality (e.g., Fuch's dystrophy)
• Abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose)
• Abnormal corneal sensitivity test (e.g., Schirmer test or similar tear production test)
• No concurrent ocular inflammation or infection

Other:

• No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or curatively treated carcinoma in situ of the cervix
• No prior allergic reaction attributed to compounds of similar biological or chemical composition to erlotinib
• No other concurrent serious illness or medical condition that would preclude study
• No prior significant neurologic or psychiatric disorder that would preclude study
• No active uncontrolled infection
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• No prior chemotherapy for endometrial cancer

Endocrine therapy:

• No more than 1 prior hormonal therapy (progestational agent or aromatase inhibitor) in the adjuvant or metastatic setting
• At least 1 week since prior hormonal therapy

Radiotherapy:

• At least 4 weeks since prior radiotherapy (except for low-dose palliative radiotherapy) and recovered

Surgery:

• At least 3 weeks since prior major surgery and recovered
• No prior surgical procedures affecting absorption
• No concurrent ophthalmic surgery

Other:

• No prior EGFR-targeting therapies
• No other concurrent investigational therapy
• No other concurrent anticancer therapy
• Concurrent oral anticoagulants (e.g., warfarin) allowed provided there is increased vigilance with respect to monitoring INR
• Concurrent low molecular weight heparin allowed at investigator's discretion

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

NCIC Clinical Trials Group

NETWORK

Sponsor Role: collaborator

National Cancer Institute (NCI)

NIH

Sponsor Role: lead

Principal Investigators

Amit M. Oza, MD

Role: STUDY_CHAIR

Princess Margaret Hospital, Canada

Locations

Tom Baker Cancer Center - Calgary

Calgary, Alberta, Canada

Cross Cancer Institute

Edmonton, Alberta, Canada

British Columbia Cancer Agency

Vancouver, British Columbia, Canada

Margaret and Charles Juravinski Cancer Centre

Hamilton, Ontario, Canada

Kingston Regional Cancer Centre

Kingston, Ontario, Canada

Cancer Care Ontario-London Regional Cancer Centre

London, Ontario, Canada

Princess Margaret Hospital

Toronto, Ontario, Canada

Hopital Notre- Dame du CHUM

Montreal, Quebec, Canada

Countries

Canada

References

Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol. 2008 Sep 10;26(26):4319-25. doi: 10.1200/JCO.2007.15.8808. Epub 2008 Jun 30.

Reference Type: RESULT

PMID: 18591547 (View on PubMed)

Oza A, Elit L, Eisenhauer E, et al.: Phase II study of erlotinib (Tarceva, OSI 774) in women with recurrent or metastatic endometrial cancer -- NCIC IND.148. [Abstract] Clin Cancer Res 9 (Suppl): A-105, 6094s, 2003.

Reference Type: RESULT

Other Identifiers

CAN-NCIC-IND148

Identifier Type: -

Identifier Source: secondary_id

NCI-NCIC-148

Identifier Type: -

Identifier Source: secondary_id

CDR0000069169

Identifier Type: OTHER

Identifier Source: secondary_id

I148

Identifier Type: -

Identifier Source: org_study_id